Last Marrow Standing: Bone Marrow Transplantation for Acquired Bone Marrow Failure Conditions
Myelodysplastic Syndromes (M Sekeres, Section Editor)
First Online: 14 October 2012 DOI:
10.1007/s11899-012-0138-x Cite this article as: Gerds, A.T. & Scott, B.L. Curr Hematol Malig Rep (2012) 7: 292. doi:10.1007/s11899-012-0138-x Abstract
Paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome are a spectrum of acquired marrow failure, having a common pathologic thread of both immune dysregulation and the development of abnormal hematopoiesis. Allogeneic hematopoietic cell transplantation plays a critical role in the treatment of these disorders and, for many patients, is the only treatment modality with demonstrated curative potential. In recent years, there have been many breakthroughs in the understanding of the pathogenesis of these uncommon disorders. The subsequent advances in non-transplant therapies, along with concurrent improvement in outcomes after hematopoietic cell transplantation, necessitate continual appraisal of the indications, timing, and approaches to transplantation for acquired marrow failure syndromes. We review here contemporary and critical new findings driving current treatment decisions.
Keywords Bone marrow transplant Myelodysplastic syndrome Aplastic anemia Paroxysmal nocturnal hemoglobinuria References Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Araten DJ, Swirsky D, Karadimitris A, et al. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria (Review). Br J Haematol. 2001;115:360–8.
Pu JJ, Hu R, Mukhina GL, et al. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica. 2012;97:1225–33.
Dingli D, Luzzatto L, Pacheco JM. Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA. 2008;105:18496–500.
Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria (Review). Exp Hematol. 2007;35:523–33.
Inoue N, Izui-Sarumaru T, Murakami Y, et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006;108:4232–6.
• Santarone S, Bacigalupo A, Risitano AM, et al. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica. 2010;95:983–8.
This paper describes the outcomes of a sizeable cohort of patients who underwent HCT for PNH.
Farah R, Franke G, Gregory TB. Hematopoietic cell transplantation after reduced intensity conditioning for severe paroxysmal nocturnal hemoglobinuria. Blood. 2011;118:2047. abstract.
• de Latour RP, Schrezenmeier H, Bacigalupo A. Allogeneic hematopoietic stem cell transplantation in paroxysmal nocturnal hemoglobinuria: A transplant versus no transplant matched comparison study on behalf of the Severe Aplastic Anemia Working Party (SAA WP) of the European Group for Blood and Marrow Transplantation (EBMT) Group and the French Society of Hematology (SFH). Blood. 2011;118:2403.
In this abstract the authors describe an elegant matched-pair analysis comparing outcomes of patients who underwent HCT versus those who did not.
•• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–92.
This study describes the long-term survival advantage seen with eculizumab in patients with PNH.
Fridkis-Hareli M, Storek M, Mazsaroff I, et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood. 2011;118:4705–13.
Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica. 2009;94:310–2.
Piccin A, McCann S, Socie G, et al. Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMT. Bone Marrow Transplant. 2010;45:1008–13.
Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after transplantation for acquired aplastic anemia using HLA-identical sibling donors. Haematologica. 2010;95:2119–25.
•• Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia (Review). Br J Haematol. 2009;147:43–70.
This review paper sets the guidelines for the current treatment approach to patients with aplastic anemia.
Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130:747–51.
• Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118:2351–7.
This paper describes the current experience with a novel conditioning regimen that incorporates alemtuzumab resulting in an excellent overall survival and a significantly lower incidence of GVHD.
• Bacigalupo A, Socié G, Schrezenmeier H, et al. Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups. Haematologica. 2012;97:1142–8.
This study is the most recent in a series of papers establishing bone marrow as the preferred graft source over peripheral blood in patients undergoing HCT for aplastic anemia.
Hows J, Stone JV, Camitta BM. Alternative donor bone marrow transplantation for severe acquired aplastic anemia. In: Schrezenmeier H, Bacigalupo A, editors. Aplastic Anemia: Pathophysiology and Treatment. Cambridge: Cambridge University Press; 1999. p. 258–74.
Bacigalupo A. Socie' G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95:976–82.
• Kim H, Kim BS, Kim DH, et al. Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia: multivariate and propensity score-matched analysis. Biol Blood Marrow Transplant. 2011;17:1289–98.
When controlling for various factors by the use of a matched-pair analysis, the results of this study suggest that outcomes are similar in patients who have a matched donor whether they are related or unrelated.
Peffault de Latour R, Purtill D, Ruggeri A, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2011;17:78–85.
Gormley NJ, Wilder J, Khuu H, et al. Co-infusion of allogeneic cord blood with haploidentical CD34+ cells improved transplant outcome for patients with severe aplastic anemia undergoing cord blood transplantation. Blood. 2011;118:654.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88 [erratum appears in Blood 1998 Feb 1;91(3):1100].
Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.
Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90:1168–78.
Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011;29:1963–70.
•• Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–9.
This paper describes the novel cytogenetic classification system for MDS that will be incorporated into the revised IPSS. It summarizes the prognostic value of the most commonly seen cytogenetic abnormalities seen in MDS.
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.
This paper describes the improvement in post-transplant outcomes over time and identifies contributing factors to that improvement.
Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306:1874–83.
Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–46.
•• Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010;28:405–11.
This study analyzed the results of a large number of patients who underwent HCT for MDS. It compares the outcomes of patients who undergo high intensity versus reduced intensity conditioning regimens, and notes the heavy influence of pre-transplant disease burden on post-transplant outcomes.
Scott BL, Storer B, Loken M, et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11:65–73.
Yakoub-Agha I, de La Salmonière P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation. J Clin Oncol. 2000;18:963–71.
Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19:396–401.
Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–400.
Lubbert M, Bertz H, Ruter B, et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009;44:585–8.
Gerds AT, Gooley TA, Estey EH, et al. Pre-transplant therapy with azacitidine verus induction chemotherapy and post-transplant outcome in patients with MDS. Biol Blood Marrow Transplant. 2012;18:1211–8.
• de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116:5420–31.
This paper describes the use of azacitidine in a prophylactic strategy after transplantation in order to reduce post-transplant relapse in a group of high-risk patients with MDS or AML.
Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26:381–9.
Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116:129–39.
Dennis M, Goodyear O, Loke J, et al. Azacitidine induces expansion of regulatory T cells and tumour specific CD8+ T lymphocytes after allogeneic stem cell transplantation: A strategy for epigenetic manipulation of a graft-versus-leukemia response. Blood. 2011;118:324.
Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110:1397–400.
Chu R, Brazauskas R, Kan F, et al. Comparison of outcomes after transplantation of G-CSF stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2011;17:1018–24.
Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011;118:2618–21.
PubMed CrossRef Copyright information
© Springer Science+Business Media New York 2012